http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8582497&from=rss RNS Number : 0970DSummit Corporation PLC10 May 2012   Summit Corporation plc ('Summit' or 'the Company')     GRANT OF OPTIONS   Oxford, UK, 10 May 2012, Summit (AIM: SUMM), a UK drug discovery company, today announces that on 10 May 2012 it granted Share Options ... Thu, 10 May 2012 14:04:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8570533&from=rss This announcement replaces RNS Number HUG1606130, which was released at 7.01 a.m. on 26 April 2012. There is no change in the underlying number of shares held but the percentage of voting rights has been amended from 3.08% to 3.06%. [TABLE NOT SHOWN] [TABLE NOT SHOWN] [TABLE NOT... Fri, 27 Apr 2012 16:07:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8567723&from=rss [TABLE NOT SHOWN] [TABLE NOT SHOWN] [TABLE NOT SHOWN]This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.The owner of this announcement warrants that:(i) the releases contained herein are protected by copyright and other applicable laws; and(ii)... Thu, 26 Apr 2012 07:01:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8564869&from=rss Summit Corporation plc ('Summit' or 'the Company') SUMMIT RECEIVES REGULATORY APPROVAL TO ENTER SMT C1100 INTO A PHASE I CLINICAL TRIAL Oxford, UK, 24 April 2012, Summit (AIM: SUMM), a UK drug discovery company, today announces that its Phase I Clinical Trial Application ('CTA')... Tue, 24 Apr 2012 07:00:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8564104&from=rss Summit Corporation plc ('Summit' or 'the Company') APPLICATION TO TRADING Oxford, UK, 23 April 2012, Summit (AIM: SUMM), a UK drug discovery company, announces that, further to the passing of the resolutions at the General Meeting of the Company on 20 April 2012, application has ... Mon, 23 Apr 2012 11:30:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8562675&from=rss Summit Corporation plc ('Summit' or 'the Company') RESULT OF GENERAL MEETING Oxford, UK, 20 April 2012, Summit (AIM: SUMM), a UK drug discovery company, announces that at a General Meeting of the Company held earlier today, the resolutions, as set out in the Notice of General Meeting... Fri, 20 Apr 2012 11:30:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8557364&from=rss Summit Corporation plc ('Summit' or 'the Company') COMPANY UPDATE: FUTURE BOARD CHANGES Oxford, UK, 16 April 2012, Summit (AIM: SUMM), a UK drug discovery company, today announces that it intends to make changes to the Board of Directors to provide additional commercial focus for... Mon, 16 Apr 2012 14:00:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8549284&from=rss Summit Corporation plc ('Summit' or 'the Company') POSTING OF SHAREHOLDER CIRCULAR Oxford, UK, 5 April 2012, Summit (AIM: SUMM), a UK drug discovery company, today announces that the Circular to Shareholders and Notice of General Meeting ('Circular') have been posted to shareholders. ... Thu, 05 Apr 2012 07:00:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8549386&from=rss Summit Corporation plc ('Summit' or 'the Company') DIRECTOR AND PDMR SHARE DEALINGS Oxford, UK, 5 April 2012, Summit (AIM: SUMM), a UK drug discovery company, has been notified that Mr Glyn Edwards, Chief Executive Officer of Summit, purchased 400,000 Ordinary Shares of 1 pence each ... Thu, 05 Apr 2012 07:00:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8547935&from=rss Summit Corporation plc ('Summit' or 'the Company') SUCCESSFUL COMPLETION OF PRECLINICAL DEVELOPMENT STUDIES IN C. DIFFICILE PROGRAMME * SMT 19969 displays excellent safety profile and will advance towards human clinical trials  Oxford, UK, 4 April 2012, Summit (AIM:... Wed, 04 Apr 2012 07:01:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8547934&from=rss Summit Corporation plc ('Summit' or 'the Company') GLYN EDWARDS APPOINTED AS CHIEF EXECUTIVE OFFICER OF SUMMIT Oxford, UK, 4 April 2012, Summit (AIM: SUMM), a UK drug discovery company, today announces that Mr Glyn Edwards has been appointed as the Company's new Chief Executive Officer.... Wed, 04 Apr 2012 07:01:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8547933&from=rss Summit Corporation plc ("Summit" or "the Company") PRELIMINARY RESULTS FOR THE YEAR ENDED 31 JANUARY 2012 Oxford, UK, 4 April 2012, Summit (AIM: SUMM), a UK drug discovery company with a portfolio of drug programmes and an innovative Seglin(TM) technology platform for the discovery... Wed, 04 Apr 2012 07:01:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8547932&from=rss Summit Corporation plc ('Summit' or 'the Company') PROPOSED PLACING OF NEW ORDINARY SHARES TO RAISE £5.0 MILLION Oxford, UK, 4 April 2012, Summit (AIM: SUMM), a UK drug discovery company, today announces a share issue to raise £5.0 million (before expenses) through the issue of 166,666,670... Wed, 04 Apr 2012 07:01:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8517734&from=rss Summit Corporation plc ('Summit' or 'the Company') RESEARCH UPDATE ON ALZHEIMER'S DISEASE PROGRAMME * Seglin OGA enzyme inhibitors gain access to the brain in in vivo studies  * Neurodegeneration expert Dr. Ann Hayes appointed as consultant  Oxford,... Tue, 06 Mar 2012 07:00:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:SUMM.L&display=news&action=article&articleid=8496836&from=rss Summit Corporation plc ('Summit' or 'the Company') SUMMIT OUTLINES CLINICAL TRIAL PLANS FOR ITS DUCHENNE MUSCULAR DYSTROPHY PROGRAMME * Clinical Trial Application expected to be submitted in Q1 2012  * Headline results from Phase I study anticipated in Q3 2012  ... Tue, 14 Feb 2012 07:00:00 GMT